Hussman Strategic Advisors Inc. Makes New Investment in Haemonetics Corporation $HAE

Hussman Strategic Advisors Inc. bought a new stake in Haemonetics Corporation (NYSE:HAE) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 10,500 shares of the medical instruments supplier’s stock, valued at approximately $512,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Haemonetics by 3.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock valued at $1,877,000 after purchasing an additional 971 shares during the last quarter. Caxton Associates LLP purchased a new position in shares of Haemonetics during the first quarter valued at approximately $216,000. United Services Automobile Association bought a new position in shares of Haemonetics during the first quarter valued at approximately $212,000. Empowered Funds LLC raised its holdings in shares of Haemonetics by 9.1% during the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after acquiring an additional 372 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Haemonetics by 6.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after acquiring an additional 9,051 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Haemonetics Stock Performance

Haemonetics stock opened at $66.10 on Thursday. The company has a quick ratio of 1.03, a current ratio of 1.64 and a debt-to-equity ratio of 1.08. The company has a market capitalization of $3.09 billion, a P/E ratio of 19.33, a PEG ratio of 1.41 and a beta of 0.29. The stock’s 50 day moving average is $78.90 and its 200 day moving average is $65.57. Haemonetics Corporation has a twelve month low of $47.31 and a twelve month high of $87.32.

Haemonetics (NYSE:HAE) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a return on equity of 27.22% and a net margin of 12.67%.The business had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. During the same quarter in the previous year, the business earned $1.12 earnings per share. The firm’s quarterly revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. On average, equities research analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Raymond James Financial reissued an “outperform” rating and set a $90.00 price objective on shares of Haemonetics in a research report on Friday, November 14th. Citigroup lowered their price objective on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a report on Tuesday, October 7th. BTIG Research reiterated a “buy” rating and set a $88.00 target price on shares of Haemonetics in a report on Friday, January 9th. Needham & Company LLC cut Haemonetics from a “buy” rating to a “hold” rating in a research note on Monday, December 15th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Haemonetics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $84.40.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.